Table 6.
Multivariate analyses of risk factors for overall survival
| Variable | SD |
URD |
||||||
|---|---|---|---|---|---|---|---|---|
| n | RR | 95% CI | P | n | RR | 95% CI | P | |
| Treatment category | .02 | |||||||
| 1: MA + TBI + PBSC | 709 | 1.00 | ||||||
| 2: MA + TBI + BM | 245 | 0.79 | 0.63-1.00 | .05 | ||||
| 3: MA + nonTBI + PBSC | 1017 | 1.02 | 0.88-1.18 | .81 | ||||
| 4: MA + nonTBI + BM | 492 | 0.78 | 0.65-0.94 | .01 | ||||
| 5: RIC + PBSC | 622 | 0.97 | 0.83-1.14 | .73 | ||||
| 6: RIC + BM | 67 | 0.85 | 0.57-1.26 | .42 | ||||
| GVHD prophylaxis | .04 | |||||||
| CSA + MTX ± other | 2645 | 1.00 | ||||||
| Tacrolimus ± MTX ± other | 484 | 0.83 | 0.72-0.96 | .01 | ||||
| Other | 23 | 1.07 | 0.6-1.90 | .82 | ||||
| Recipient age, y | < .0001 | .0002 | ||||||
| 20-39 | 1342 | 1.00 | 940 | 1.00 | ||||
| 40-49 | 866 | 1.28 | 1.12-1.46 | .0004 | 644 | 1.24 | 1.09-1.42 | .001 |
| 50+ | 944 | 1.59 | 1.39-1.82 | < .0001 | 786 | 1.29 | 1.13-1.46 | .0001 |
| Donor age, y | ||||||||
| 18-29 | 710 | 1.00 | ||||||
| ≥ 30 | 1669 | 1.19 | 1.07-1.34 | .002 | ||||
| KPS | < .0001 | < .0001 | ||||||
| < 80 | 256 | 1.00 | 216 | 1.00 | ||||
| 80-100 | 2789 | 0.52 | 0.45-0.61 | < .0001 | 1906 | 0.68 | 0.58-0.81 | < .0001 |
| Unknown | 107 | 0.64 | 0.47-0.86 | .004 | 248 | 0.59 | 0.47-0.74 | < .0001 |
| Disease | < .0001 | .02 | ||||||
| ALL | 505 | 1.00 | 446 | 1.00 | ||||
| AML | 1362 | 0.68 | 0.59-0.80 | < .0001 | 1044 | 0.87 | 0.75-1.00 | .05 |
| CML | 828 | 0.58 | 0.48-0.70 | < .0001 | 463 | 0.81 | 0.68-0.97 | .02 |
| MDS | 457 | 0.53 | 0.43-0.66 | < .0001 | 417 | 0.74 | 0.60-0.91 | .005 |
| Disease status at transplant | < .0001 | < .0001 | ||||||
| Early | 1750 | 1.00 | 907 | 1.00 | ||||
| Intermediate | 520 | 1.51 | 1.31-1.75 | < .0001 | 568 | 1.28 | 1.11-1.47 | .0007 |
| Advanced | 666 | 2.23 | 1.95-2.55 | < .0001 | 707 | 2.15 | 1.88-2.46 | < .0001 |
| Unknown | 216 | 1.56 | 1.22-2.00 | .0004 | 188 | 1.74 | 1.35-2.24 | < .0001 |
| Sex mismatch (D/R) | .0008 | |||||||
| M/M, M/F, F/F | 2397 | 1.00 | ||||||
| F/M | 746 | 1.25 | 1.11-1.40 | .0002 | ||||
| Missing | 9 | 0.69 | 0.17-2.78 | .60 | ||||
| R/D CMV serostatus | .003 | |||||||
| NN | 738 | 1.00 | ||||||
| NP/PN/PP | 1586 | 1.19 | 1.06-1.33 | .003 | ||||
| Missing | 46 | 1.57 | 1.03-2.37 | .03 | ||||
| ABO match | .02 | |||||||
| Match | 988 | 1.00 | ||||||
| Mismatch | 1370 | 1.17 | 1.05-1.30 | .004 | ||||
| Missing | 12 | 1.00 | 0.48-2.12 | .99 | ||||
| HLA match | < .0001 | |||||||
| 8/8 matched | 1532 | 1.00 | ||||||
| 7/8 matched | 614 | 1.23 | 1.09-1.38 | .0006 | ||||
| ≤ 6/8 matched | 224 | 1.68 | 1.42-1.98 | < .0001 | ||||
Pairwise comparisons significant for the treatment categories were as follows for SD, treatment category 2 versus treatment category 3 (P = .03), treatment category 3 versus treatment category 4 (P = .003) and treatment category 4 versus treatment category 5 (P = .03); and for URD, none.
RR, relative risk; KPS, Karnofsky performance score; MDS, myelodysplastic syndrome; D, donor; R, recipient; M, male; F, female; N, negative; P, positive; CSA, cyclosporine; MTX, methotrexate; and MA, myeloablative.